---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-279788"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-06-23T21:19:36+00:00"
generated_at: "2026-06-23T21:20:18.301114+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics appoints Robert Azelby to board; receives option for 35,910 shares at $27.97

## Summary
- Board expanded to seven directors; Azelby fills newly created vacancy as Class II director term expiring 2029.
- Azelby is independent; will serve on Compensation and Nominating/Corporate Governance committees.
- Receives equity: option to purchase 35,910 shares at $27.97, plus RSU for 5,740 shares, vesting over 3 years.
- Annual retainer of $45,000 for board service plus committee retainers of $7,500 and $5,000.
- Azelby brings 30+ years biopharma experience including Juno and Amgen; company advancing vopimetostat for pancreatic cancer.

## SEC filing metadata
- accession: 0001193125-26-279788
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-06-23T21:19:36+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/0001193125-26-279788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/d79260d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-279788
- JSON: https://secwatch.observer/filing/0001193125-26-279788.json
- Plain text: https://secwatch.observer/filing/0001193125-26-279788.txt

## Key facts
- Executive change
  Robert Azelby was appointed as Director at Tango Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/0001193125-26-279788-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.